Public Believes Dermatologic Side Effects From Cancer Treatment Are Common
By Lori Solomon HealthDay Reporter
TUESDAY, Aug. 12, 2025 -- Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates, according to a study published online in the August issue of the Journal of Drugs in Dermatology.
Nikita Menta, from George Washington University in Washington, D.C., and colleagues evaluated knowledge and perceptions of ACT (medication or radiation)-related DSEs in a medically underserved community. The analysis included survey responses from 77 individuals attending two health fairs.
The researchers found that 21 percent of respondents were previously treated for cancer. Overall, most respondents believed that ACTs cause hair loss (52 percent overall versus 31 percent of respondents previously treated for cancer), dry skin/rash (47 versus 50 percent), and nail changes (41 versus 31 percent). Respondents most frequently reported the DSEs that would make them possibly or definitely not undergo treatment were permanent hair loss (33 percent overall versus 13 percent of respondents previously treated for cancer), temporary eyebrow/eyelash hair loss (27 versus 13 percent), and permanent nail discoloration (24 versus 13 percent). Among patients who were previously treated for cancer, half did not visit a dermatologist during cancer treatment.
"These data underscore the need for improved DSE management," the authors write. "Dermatologists should educate oncologists and primary care physicians on patients’ experiences undergoing ACT and treatments for DSEs."
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Prostate Cancer Incidence Trends Increasing
WEDNESDAY, Sept. 3, 2025 -- Prostate cancer incidence is increasing, according to a report published online Sept. 2 in CA: A Cancer Journal for Clinicians. Tyler B. Kratzer...
Prefrontal Cortex Can Be Safely Biopsied During Deep Brain Stimulation
WEDNESDAY, Sept. 3, 2025 -- Obtaining a prefrontal cortex (PFC) biopsy during deep brain stimulation (DBS) procedures is safe, according to a study published online Sept. 3 in...
Peer Review, Editorial Process Yield Improvements in RCT Abstracts
WEDNESDAY, Sept. 3, 2025 -- Peer review and the editorial process yield frequent improvements in research abstracts of randomized clinical trial (RCT) reports, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.